par Bel Lassen, Pierre;Kyrilli, Aglaia ;Lytrivi, Maria ;Corvilain, Bernard
Référence Annales d'Endocrinologie
Publication Publié, 2019-11-01
Référence Annales d'Endocrinologie
Publication Publié, 2019-11-01
Article révisé par les pairs
Résumé : | Subclinical hyperthyroidism is a common clinical entity, defined by serum TSH below the reference range, with normal FT4 and FT3 levels in an asymptomatic patient. Whether or not subclinical hyperthyroidism should be treated remains a matter of debate. Cross-sectional and longitudinal population-based studies demonstrate association of subclinical hyperthyroidism with risk of atrial fibrillation and osteoporosis, and with cardiovascular and all-cause mortality. However, there are no randomized clinical trials addressing whether long-term health outcomes are improved by treating subclinical hyperthyroidism; in the absence of evidence one way or the other, it seems appropriate to use decision trees taking account of TSH concentration and presence of risk factors (age > 65 years or post-menopause, osteoporosis and cardiac disease). |